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Abstract
The National Institute for Health and Care Excellence, as part of the institute’s single technology appraisal process, invited 
the manufacturer of ribociclib  (Kisqali®, Novartis) to submit evidence regarding the clinical and cost effectiveness of the 
drug in combination with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, human 
epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer. Kleijnen Systematic Reviews Ltd 
and Erasmus University Rotterdam were commissioned as the Evidence Review Group for this submission. The Evidence 
Review Group reviewed the evidence submitted by the manufacturer, corrected and validated the manufacturer’s decision 
analytic model, and conducted exploratory analyses to assess the robustness and validity of the presented clinical and cost-
effectiveness results. This article describes the company submission, the Evidence Review Group assessment and National 
Institute for Health and Care Excellence subsequent decisions. The main clinical effectiveness evidence was obtained from 
the MONALEESA-2 trial, a randomised controlled trial comparing ribociclib plus letrozole with placebo plus letrozole. 
Progression-free survival was significantly longer in the ribociclib group (95% confidence interval, 19.3–not reached) vs. 
14.7 months (95% confidence interval 13.0–16.5) in the placebo group. To assess the cost effectiveness of ribociclib in 
combination with an aromatase inhibitor, the company developed an individual patient-level model using a discrete-event 
simulation approach in  Microsoft® Excel. In the model, simulated patients move through a series of three health states until 
death, i.e. first-line progression-free survival, second-line progression-free survival and progressive disease. The length of 
progression-free survival during the first line was informed by the MONALEESA-2 trial. The benefit in progression-free 
survival in the first line was transferred to a benefit in overall survival assuming full progression-free survival to overall sur-
vival surrogacy (because of the immaturity of overall survival data from the MONALEESA-2 trial). Patient-level data from 
the BOLERO-2 trial, evaluating the addition of everolimus to exemestane in the second-line treatment of postmenopausal 
HR-positive advanced breast cancer, were used to inform the length of progression-free survival during the second line. 
Costs included in the model were treatment costs (e.g. technology acquisition costs of first, second, third and/or later line 
treatments), drug administration costs, monitoring costs and health state costs (including terminal care). Additionally, the 
costs of adverse events associated with the first-line treatment were incorporated. The Evidence Review Group recalculated 
the incremental cost-effectiveness ratio using data from a different data cut-off date from the MONALEESA-2 trial and by 
changing some assumptions (e.g. progression-free survival to overall survival surrogacy approach and post-progression third 
and/or later line treatment-related costs). After two appraisal committee meetings and a revised base case submitted by the 
company (including a second enhanced patient access scheme discount), the committee concluded that taking into account 
the uncertainties in the calculation of the cost effectiveness, there were plausible cost-effectiveness estimates broadly in 
the range that could be considered as a cost-effective use of National Health Service resources. Therefore, ribociclib was 
recommended as a treatment option for the first-line treatment of hormone receptor-positive, human epidermal growth factor 
receptor 2-negative breast cancer, contingent on the company providing ribociclib with the discount agreed in the second 
enhanced patient access scheme.
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Key Points 
Centrally assessed progression-free survival data might 
be more reliable than locally assessed progression-free 
survival data in the presence of differences in adverse-
event rates.
When the overall survival data from the trial are imma-
ture, different (e.g. partial or full) progression-free 
survival to overall survival surrogacy approaches should 
be explored in different scenario analyses, with different 
parameter realisations, which all should be taken into 
account in the decision-making process.
When there are more than one simultaneous/recent 
appraisals in the same indication, this can be beneficial 
as the results of the other appraisal might be used for 
external validation purposes.
The iterative nature of appraisal meetings may provide 
an opportunity to find a middle ground between the 
company assumptions and the Evidence Review Group 
point of view. The company may provide enhanced 
patient access scheme discounts to reduce the uncer-
tainty surrounding the cost effectiveness of the drug in 
this process.
1 Introduction
The National Institute for Health and Care Excellence 
(NICE) is an independent organisation providing national 
guidance on promoting good health and preventing and 
treating ill health. The single technology appraisal (STA) 
process is designed to provide recommendations on a 
single product, device or other technology with a sin-
gle indication [1]. The process covers new technologies 
and enables NICE to produce guidance shortly after the 
technology is introduced into UK. The NICE Appraisal 
Committee (AC) obtains relevant evidence from several 
sources: the company submission (CS) [2], a report from 
the appointed independent Evidence Review Group (ERG) 
[3] and advice from consultees (i.e. patients, experts and 
other stakeholders). The CS includes a written report and a 
mathematical model describing the clinical and cost effec-
tiveness of the technology under investigation. The ERG, 
an external organisation independent of NICE, reviews the 
CS and produces a summary report and provides a critique 
of the submitted evidence. After consideration of all the 
relevant evidence, the AC formulates preliminary guid-
ance in the form of the Appraisal Consultation Document 
(ACD) as to whether or not to recommend the interven-
tion. The stakeholders are invited to comment on this ACD 
and the submitted evidence. A subsequent ACD may be 
produced or a Final Appraisal Determination is issued. 
Once published, NICE technology guidance provides a 
legal obligation for National Health Service (NHS) pro-
viders to reimburse technologies that have been approved. 
This article presents a summary of the ERG report and 
the development of NICE guidance for the STA of riboci-
clib in combination with an aromatase inhibitor (AI), for 
treating previously untreated, hormone receptor-positive 
(HR+), human epidermal growth factor receptor 2-nega-
tive (HER2−), locally advanced or metastatic breast can-
cer. Full details of all the relevant appraisal documents can 
be found on the NICE website [4].
2  Decision Problem
Breast cancer is one of the most common cancers affecting 
women worldwide and a leading cause of cancer deaths 
[5]. Despite advances in the understanding of different 
forms of breast cancer and improvements in the treat-
ment of patients, breast cancer remains a potentially life-
threatening diagnosis, in large part because of breast can-
cer recurrence and the incurability of advanced disease; 
both remain major clinical challenges [6]. Advanced breast 
cancer is considered to include both locally advanced and 
stage IV (metastatic) cancer [7, 8], and the median sur-
vival of patients with advanced breast cancer is just 2–3 
years [9].
Breast cancer is a heterogeneous disease and there are a 
number of recognisable histological and intrinsic subtypes 
distinguished by the expression of oestrogen receptors, 
progesterone receptors and epidermal growth factor recep-
tors (e.g. HER2), and by distinct gene profiles that affect 
prognosis and outlook [10]. Around 75% of postmenopau-
sal women with breast cancer have tumours that are HR+ 
[11], and the majority of HR+ patients are HER2−; there-
fore, HR+/HER2− is the most common form of breast 
cancer [11, 12].
The current NICE pathway of care and guidance regard-
ing the therapeutic management of advanced breast cancer 
recommends endocrine therapy as the first-line treatment 
for the majority of patients [13]. According to the NICE 
pathway of care, chemotherapy should only be a first-
line option in patients whose disease is imminently life 
threatening or requires early relief of symptoms because 
of significant visceral organ involvement. In such patients, 
endocrine therapy should then be offered on completion 
of chemotherapy [13].
Ribociclib  (Kisqali®) is an oral cyclin-dependent kinase 
4 and 6 inhibitor that aims to prevent the phosphorylation 
of retinoblastoma protein and restore its growth-inhibitory 
effects. Ribociclib in combination with an AI (ribociclib plus an AI) has a UK marketing authorisation for the 
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following indication: “treatment of postmenopausal 
women with HR+, HER2− locally advanced or metastatic 
breast cancer as initial endocrine based therapy” [14].
The remit of this appraisal was specified by NICE’s 
final scope [15], which was to assess the clinical and cost 
effectiveness of ribociclib plus an AI within its licenced 
indication. The comparators listed in the scope were AIs, 
such as letrozole or anastrozole.
3  Independent Evidence Review Group 
Report
Kleijnen Systematic Reviews Ltd, in collaboration with 
Erasmus University Rotterdam, acted as the ERG, and 
reviewed the evidence on the clinical and cost effective-
ness of ribociclib plus an AI for the treatment of postmen-
opausal women with HR+/HER2−, locally advanced or 
metastatic breast cancer as initial endocrine-based therapy. 
The review embodied three aims: (1) to assess whether the 
CS conformed to the methodological guidelines issued by 
NICE [1]; (2) to assess whether the company’s interpreta-
tion and analysis of the evidence were appropriate; and 
(3) to indicate the presence of other sources of evidence 
or alternative interpretations of the evidence that could 
inform NICE guidance.
The ERG critically reviewed the evidence in the CS, the 
response to clarification questions and evidence provided 
after the publication of the ACD. Furthermore, it conducted 
additional searches, explored the impact of assumptions on 
the incremental cost-effectiveness ratio (ICER), revised the 
economic model and explored additional scenario analyses.
3.1  Critique of the Decision Problem
In the CS, findings from the MONALEESA-2 trial [16] were 
used, in which ribociclib in combination with letrozole was 
compared with letrozole alone. Other AIs such as anastro-
zole were not considered. However, the ERG believed that 
the company provided sufficient justification for the general-
isability of letrozole to other AIs. In addition, the ERG noted 
that the MONALEESA-2 trial included very few patients 
from England and Wales, and that the trial population dif-
fered from the UK population particularly in terms of endo-
crine sensitivity and the proportion of patients with de-novo 
advanced breast cancer. Thus, the ERG concluded that the 
MONALEESA-2 trial might not be entirely representative 
of the population in the NICE scope.
3.2  Summary of the Clinical Evidence
One phase III trial, MONALEESA-2 [16], with 668 
patients was presented as the main source of evidence. The 
MONALEESA-2 study included postmenopausal women 
with HR+/HER2− recurrent or metastatic breast cancer who 
had not received previous systemic therapy for advanced 
disease.
The trial was conducted at 223 trial centres in 29 coun-
tries including very few patients from England and Wales. 
Patients were randomised 1:1 to receive ribociclib (600 
mg once daily, days 1–21 of a 28-day cycle) plus letrozole 
(2.5 mg once daily, continuous treatment) or placebo plus 
letrozole (2.5 mg once daily, continuous treatment). Dose 
reductions for ribociclib (from 600 to 400 to 200 mg per 
day) were permitted to manage adverse events (AEs); no 
dose reductions were permitted for letrozole. Treatment 
was continued until disease progression, unacceptable tox-
icity, death, or discontinuation of ribociclib or letrozole 
for any other reason.
The primary outcome was progression-free survival 
(PFS) as per RECIST version 1.1 criteria, based on local 
radiological assessment; assessments were also carried out 
by a blinded independent review committee (BIRC). The 
key secondary endpoint was overall survival (OS) [defined 
as the time from the date of randomisation to the date of 
death as a result of any cause].
A total of 334 patients were randomised to ribociclib 
and 334 to placebo in the intention-to-treat population. At 
the time of the data cut-off (29 January, 2016), a total of 
349 patients (52.2%) were still receiving treatment (ribo-
ciclib, n = 195; placebo, n = 154). The rates of discon-
tinuation were 41.6% in the ribociclib group compared 
with 53.9% in the placebo group. The most frequent rea-
son for discontinuation was disease progression in both 
groups (ribociclib, 26.0%; placebo, 43.7%). Discontinu-
ations because of AEs were 7.5% in the ribociclib group 
and 2.1% in the placebo group. The median duration of 
follow-up from randomisation to the data cut-off was 15.3 
months.
In the clinical effectiveness section, the CS presented 
data from the first interim analysis only (cut-off Janu-
ary 2016) and focused on results based on local assess-
ments. Progression-free survival was significantly 
longer in the ribociclib group (95% confidence interval 
19.3–not reached) vs. 14.7 months (95% confidence inter-
val 13.0–16.5) in the placebo group. The addition of ribo-
ciclib to letrozole reduced the risk of death or progres-
sion by 44% (hazard ratio = 0.56; 95% confidence interval 
0.43–0.72).
Although there were some differences in effectiveness, 
subgroup analyses showed that results for PFS favoured 
ribociclib for all subgroups including both those with 
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newly diagnosed disease and those with existing disease 
and those who had received prior therapy and patients 
who had not. Although the occurrence of any AEs was 
overall similar in ribociclib and placebo groups, a greater 
number of AEs and severe AEs were attributable to ribo-
ciclib. The most common event was neutropenia. Gastro-
intestinal events such as nausea, vomiting and diarrhoea 
occurred more frequently in the ribociclib group. The 
submission did not meet the criteria for end of life as the 
life expectancy for patients with newly diagnosed HR+/
HER2− advanced breast cancer is greater than 24 months.
3.3  Critique of the Clinical Evidence
The company searched a good range of databases and con-
ference proceedings and carried out searches in accordance 
with NICE guidance. However, no literature searches were 
conducted to identify AE data, indirect and mixed treat-
ment comparisons or non-randomised and non-controlled 
evidence.
The clinical effectiveness evidence in the submission was 
based on one trial, the MONALEESA-2 study. The ERG 
was not aware of any other evidence relevant to the decision 
problem. Overall, the MONALEESA-2 trial was a good-
quality randomised controlled trial. However, increased rates 
of AEs, such as neutropenia (74% in the ribociclib group vs. 
5% in the letrozole group), could have unblinded physicians 
and/or patients. Therefore, results based on independent 
reviews were deemed to be more reliable.
The main concern regarding the methodology of the 
MONALEESA-2 trial was that the initial results presented 
in the CS were based on data from the January 2016 cut-off 
for PFS. At this point, the OS data were immature as the 
required number of deaths had not been reached, with 43 
deaths (23 in the ribociclib group and 20 in the placebo 
group) at the time of the data cut-off. The ERG identified two 
more recent interim analyses from the MONALEESA-2 trial 
after the January 2016 cut-off (June 2016 and January 2017), 
and requested these data as part of the clarification process. 
The ERG considered OS results from the most recent data 
cut-off (January 2017) the most informative. Additionally, 
the ERG considered the BIRC results more plausible for 
PFS, partly because the NICE committee preferred these 
data in a recent technology appraisal (TA495: palbociclib in 
the first line treatment of HR+/HER2− advanced breast can-
cer) [17], and partly because the increased AEs in the ribo-
ciclib arm could have unblinded physicians and/or patients; 
therefore, making results based on independent reviews 
more reliable. Unfortunately, BIRC results were not avail-
able at the latest (January 2017) data cut-off; therefore, the 
ERG considered the BIRC PFS results from the June 2016 
cut-off to be the most appropriate.
The PFS results were more favourable for ribociclib in the 
company preferred results compared with the ERG preferred 
results. Using the latest data cut-off, OS Kaplan–Meier 
(KM) curves were still rather immature and there appeared 
to be insufficient evidence from the MONALEESA-2 trial 
to argue that ribociclib improves OS.
3.4  Summary of the Cost‑Effectiveness Evidence
The company developed an individual patient-level model, 
following a discrete-event simulation approach, to assess 
the cost effectiveness of ribociclib plus an AI for previously 
untreated advanced or metastatic HR+/HER2− breast can-
cer. Letrozole was considered as representative of the avail-
able AI therapies, both in terms of clinical effectiveness and 
costs. In the model, simulated patients move through a series 
of health states; these include first-line PFS (PFS1), second-
line PFS (PFS2), progressed disease (later lines) and death. 
A lifetime horizon was chosen and costs and effects were 
discounted with an annual rate of 3.5%.
All patients start in the PFS1 state, in which they receive 
either ribociclib in combination with letrozole or letrozole 
alone. Patients stay in this state until they progress and move 
to the PFS2 state, or until they die. Second-line PFS repre-
sents the time between disease progression in first- and sec-
ond-line treatment cessation (as a proxy for disease progres-
sion). In the PFS2 state, patients receive one of the following 
treatments: everolimus in combination with exemestane, 
exemestane (representing a single-agent endocrine therapy) 
Fig. 1  Model structure. PFS 1 first-line progression-free survival, 
PFS 2 second-line progression-free survival
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or capecitabine (representing chemotherapy). Patients stay 
in this state until they progress and move to the progressed 
disease state, or until they die. The progressed disease state 
represents the time from second-line therapy cessation (as a 
proxy for progression) until death, and in this state, patients 
receive subsequent treatments and/or supportive/palliative 
care. The death state is an absorbing state. The model struc-
ture is illustrated in Fig. 1.
For the PFS1 state, the relevant clinical model inputs for 
the ribociclib plus an AI and AI monotherapy arms were 
time to treatment discontinuation (TTD), PFS and the pro-
portion of death among the PFS events. These inputs were 
derived from the analysis of data from the June 2016 cut-off 
of the MONALEESA-2 trial.
For the extrapolation of the PFS of the ribociclib plus an 
AI and AI arms from the MONALEESA-2 trial, an exponen-
tial distribution was considered to be the most appropriate, 
considering the plausibility of the long-term extrapolation 
to the external KM data from other trials in which letrozole 
monotherapy was a comparator (PALOMA-2 [18], LEA [19] 
and ALLIANCE trials [20]). The survival extrapolation of 
the TTD in the first line was conducted independently and 
based on clinical expert opinion and model predictions. 
The company selected the exponential distribution for the 
base case and alternative distributions were explored in sce-
nario analyses, taking into account a time constraint, which 
assured that the TTD was never greater than PFS.
After the first-line treatment, it was assumed that the dis-
tribution of treatments received in the PFS2 state (exemes-
tane monotherapy, everolimus plus exemestane or chemo-
therapy) were different after ribociclib plus an AI and AI 
monotherapy arms. These estimates were based on clinical 
opinion and the impact of assuming different treatment dis-
tributions was explored in scenario analyses.
In the second line, TTD data from the BOLERO-2 trial 
[21] (comparing everolimus plus exemestane with exemes-
tane in second-line HR+/HER2− breast cancer) were used 
as a proxy for PFS. For the patients who received everolimus 
plus exemestane, a Weibull distribution was deemed to be 
the most appropriate by the company, based on its visual fit 
to the TTD KM curve from the trial. For the TTD of exemes-
tane monotherapy and chemotherapy, hazard ratios from the 
BOLERO-2 trial and a study by Li et al. [22] were applied 
to the fitted Weibull curve, respectively.
The probability of death before treatment discontinuation 
in the second line was derived from the analysis of patient-
level data from the BOLERO-2 trial for patients receiving 
everolimus plus exemestane combination therapy or exemes-
tane monotherapy in the PFS2 state. No death before treat-
ment discontinuation was assumed for patients receiving 
chemotherapy in the PFS2 state.
The company used the pooled post-treatment discon-
tinuation survival data as a proxy for the post-progression 
survival in the BOLERO-2 trial, based on the observed 
similarity of the KM curves shown in the CS. A range of 
parametric survival models were fitted to the pooled data 
and the Weibull distribution was chosen to model the post-
discontinuation survival after everolimus plus exemestane 
combination therapy or exemestane monotherapy in the 
PFS2 state, based on the statistical and visual fit. For the 
post-discontinuation survival under chemotherapy, the haz-
ard ratios reported in Li et al. [22] were used. Alternative 
distributions for the modelling of the post-discontinuation 
survival were explored in the scenario analyses in the CS.
In the model, OS is modelled indirectly, and is a function 
of the time spent in each of the alive health states (PFS1, 
PFS2 and progressed disease). In the model, in the base case, 
a full PFS to OS surrogacy approach was followed. In this 
Fig. 2  Illustration of the full progression-free survival (PFS) to overall survival (OS) surrogacy approach. PD progressive disease, PFS1 first-
line progression-free survival, PFS2 second-line progression-free survival. Source: company submission, Fig. 20, p. 102
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approach, it is assumed that a gain in PFS would lead to 
an equal gain in OS, for the patients who did not die upon 
progression as depicted in Fig. 2.
In addition to the full PFS to OS surrogacy approach, 
a range of threshold-based PFS to OS surrogacy scenarios 
(from 4 to 24 months) were conducted. In these threshold-
based scenarios, a gain in PFS was translated into an equiva-
lent gain in OS only if a pre-defined threshold is exceeded. 
The threshold was defined either in terms of the absolute 
PFS under ribociclib with letrozole or in terms of the PFS 
gain of ribociclib in combination with letrozole compared 
to letrozole monotherapy. A schematic of the patient flow 
based on an absolute PFS-based threshold scenario is given 
in Fig. 3.
Utility values of patients (on and off treatment) in the 
PFS1 state were derived from the statistical analysis of EQ-
5D-5L data collected in the MONALEESA-2 trial. Utility 
values for PFS2 were taken from Lloyd et al. [23] adjusted 
for age and treatment response (the latter based on the 
BOLERO-2 study). For patients treated with second-line 
chemotherapy, a utility decrement was applied, in line with 
the findings of Peasgood et al. [24]. Utility values for the 
progressed disease state were taken from TA495 [17], which 
were derived from Lloyd et al. [23], as well, adjusted for age.
Treatment costs (e.g. technology acquisition costs of first, 
second, third and later line treatments), drug administra-
tion costs, monitoring costs and health state costs (including 
terminal care) were included in the model. Additionally, the 
costs of AEs associated with the first-line treatment were 
incorporated. All costs used in the model calculations were 
based on their 2016 values.
The prices of generic treatments (e.g. letrozole) were 
taken from the electronic market information tool (eMIT) 
[25]. Non-generic drug prices were taken from the British 
National Formulary [26]. For ribociclib, the company pro-
posed a patient access scheme (PAS) discount in its submis-
sion and for everolimus, another PAS price discount was 
already available for the NHS.
The licenced dose for ribociclib is 600 mg once daily for 
21 days of a 28-day cycle, which consists of three 200-mg 
tablets. Ribociclib 200 mg is available in packs of 63, 42 
and 21 tablets, with a pricing structure such that each 200-
mg tablet has the same price regardless of the pack size. A 
proportion of patients in MONALEESA-2 had their dose 
reduced to 400 mg and 200 mg daily. The company assumed 
that patients who reduce their dose do not waste tablets as 
they can simply take fewer tablets daily, and therefore a pack 
lasts longer. The company used individual patient data to 
calculate the total number of days patients received 600 mg, 
400 mg or 200 mg at each cycle until the ninth cycle, and 
cycle 10 data were used for cycle 10 and onwards owing to 
decreasing patient numbers.
The drug dosage and treatment duration data for everoli-
mus and/or exemestane in the second line were derived from 
the BOLERO-2 study. Capecitabine was assumed as the rep-
resentative chemotherapy administered in the second line 
and its dosage and duration data were taken from the NICE 
clinical guideline for breast cancer [27].
For the progression health state, drug acquisition costs 
were estimated to be £461.54 per week (i.e. £2000 per 
month), based on clinical expert opinion. Monitoring costs 
for ribociclib were incorporated in line with the anticipated 
licence of ribociclib. Ribociclib, letrozole, everolimus 
and exemestane are all administered orally, and the drug 
administration costs for chemotherapy were based on NHS 
reference costs and previous NICE technology appraisals. 
The costs associated with the management of the disease 
were estimated based on the package of resource use for 
Fig. 3  Illustration of the patient flow in an absolute, progression-free survival (PFS)-based threshold scenario. OS overall survival, PD progres-
sive disease, PFS1 first-line progression free survival, PFS2 second-line progression-free survival. Source: company submission, Fig. 21, p. 103
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advanced breast cancer recommended in the NICE clinical 
guideline 81, previous NICE technology appraisals in HR+/
HER2− advanced breast cancer (TA421 [28] and TA495 
[17]) and validation through clinical experts. Costs of grade 
3 or 4 AEs were based on NHS reference costs.
Without the PAS, incremental quality-adjusted life-years 
(QALYs) were 0.96 and ICER values, which were confiden-
tial, were above the accepted willingness-to-pay threshold of 
£30,000/QALY. With the PAS, incremental costs reduced to 
such an extent that the resulting ICER was around £30,000/
QALY. Quality-adjusted life-years were predominantly 
gained within the PFS1 state, and the increase in costs is 
mainly caused by the increase in first-line treatment costs. 
The probabilistic sensitivity analysis results were in line 
with the deterministic base-case results. Within the deter-
ministic sensitivity analyses, the company varied some of 
the input parameters to its upper and lower limits. This 
analysis showed that the ICER was most sensitive to the 
discount rates.
Furthermore, the company performed several scenario 
analyses. A time horizon of 5 or 10 years (instead of 40 
years), the use of a Weibull or Gompertz parametric function 
for first-line PFS (instead of an exponential function) and 
the use of different threshold-based PFS to OS surrogacy 
approaches (instead of a full PFS to OS surrogacy approach) 
had the largest impacts on the ICER both with and without 
PAS. The use of lower post-progression treatment costs for 
the progressed disease health state (i.e. £1000, £425, or £0 
per month instead of £2000 per month) increased the ICER.
3.5  Critique of the Cost‑Effectiveness Evidence
The cost-effectiveness searches in the CS were well docu-
mented, reproducible and were carried out in line with the 
NICE guide to the methods of technology appraisal. The 
model structure followed in this appraisal (patient-level sim-
ulation with four health states; PFS1, PFS2, progressive dis-
ease and death) was different from most of the other oncol-
ogy economic models in NICE technology appraisals, which 
have used a partitioned survival approach, extrapolating 
PFS and OS from clinical trial data [29, 30]. Because of the 
immaturity of the OS data, the OS in the CS was modelled 
indirectly and is a sum of the time spent in each of the alive 
health states. In the base case, it was assumed that any gain 
in PFS was 100% translated into OS gain. The ERG consid-
ered this assumption to be speculative, as there are studies 
indicating that the duration of PFS gain would translate into 
an OS gain that is shorter, especially in HER2− patients, 
which can be also seen in the PALOMA-1 trial [31] (com-
paring palbociclib plus letrozole vs. letrozole) where a “gain 
in median OS/gain in median PFS” ratio close to 38.5% was 
observed. The ERG considered the observed ratio of 38.5% 
to be more plausible than the completely arbitrary 100% 
or threshold-based PFS to OS surrogacy scenarios that the 
company assumed.
In addition to the PFS to OS surrogacy approach, using 
PFS and OS data from a different study (BOLERO-2) to 
inform the model on time spent in PFS2 and PD states, with-
out any adjustments, assumes that the BOLERO-2 trial was 
conducted subsequent to the MONALEESA-2 trial, just after 
the patients progressed after the first-line therapy. Instead, 
the ERG would have preferred an approach where the OS 
and PFS parametric functions used from the BOLERO-2 
trial were adjusted based on the patient characteristics at 
disease progression from the first-line treatment (e.g. age, 
previous treatment, Eastern Cooperative Oncology Group 
disease status, time since diagnosis at the time of first-
line treatment progression). The use of such adjusted and 
matched OS and PFS survival functions from BOLERO-2 
might have an impact on the cost-effectiveness results.
In the company base case, time-to-event related model 
inputs for the PFS1 state (i.e. PFS and TTD) were based 
on the June 2016 cut-off of the MONALEESA-2 trial. The 
ERG considered that data from the latest cut-off (January 
2017) should have been used in the model. The company 
provided January 2017 data only for PFS that is based on 
the local assessment. Time to treatment discontinuation and 
PFS based on a central assessment from the January 2017 
cut-off were not provided.
For the extrapolation of the PFS in the first line, the ERG 
disagreed with the company that the exponential distribution 
provided the best fit to the external data from other clini-
cal trials. According to the ERG, the Weibull distribution, 
both for PFS and TTD, would be at least as plausible as the 
exponential distribution.
For the estimation of drug acquisition costs in the pro-
gression health state, the company used expert opinion. 
However, very little information was provided on the details 
of what was suggested by the experts to arrive at these costs. 
Thus, the ERG was not able to assess the validity of this cost 
estimate (approximately £2000 per month), and this cost 
appeared to be high, in comparison to later line drug acquisi-
tion costs in other breast cancer technology appraisals.
Other issues identified by the ERG include: not includ-
ing wastage in treatment costs (because dispensed packages 
cannot be used for other patients once a patient discontinues 
treatment), unnecessary assumptions made while fitting a 
Weibull distribution for the modelling of the post-treatment 
discontinuation survival after chemotherapy, and differential 
proportions of treatments received in the second line after 
ribociclib plus letrozole and letrozole.
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3.6  Additional Exploratory Analyses Conducted 
by the Evidence Review Group
Table 1 shows the adjustments made by the ERG to the 
company base case. The ERG preferred base case resulted 
in incremental QALYs of 0.53 and ICERs above accepted 
thresholds, even with the PAS price discount for riboci-
clib. The most influential adjustments/corrections made 
by the ERG were: (1) changing the full PFS to OS surro-
gacy approach to a partial PFS to OS surrogacy approach; 
(2) using model inputs derived from the most recent PFS 
dataset of the MONALEESA-2 trial (data cut-off January 
2017) and; (3) using an inflation-adjusted third-line treat-
ment-related cost estimate from a published NICE appraisal 
(TA239, fulvestrant) [32].
From the probabilistic sensitivity analysis results, the 
probability that ribociclib plus letrozole therapy is cost 
effective compared to letrozole monotherapy is consider-
ably lower than 50% at a £30,000/QALY threshold (with the 
PAS price). The ERG conducted some additional scenario 
analyses on their preferred base case to assess structural 
uncertainty.
In one of the scenarios, the ERG explored the impact 
of using a Weibull distribution instead of an exponential 
distribution to generate the time to event for PFS in the first 
line. The ERG considered the Weibull distribution to be at 
least as plausible as the exponential distribution. Selecting 
the Weibull distribution instead of the exponential distribu-
tion increased the ICER substantially. Scenarios with a more 
modest impact on the ICER included different trial data-
based letrozole acquisition costs from cycle 11 onwards, and 
assuming different second-line treatment proportions.
3.7  Conclusions of the Evidence Review Group 
Report
The ERG considered the searches conducted in the CS to be 
satisfactory and MONALEESA-2 [16] to be a good-quality 
randomised trial. However, the ERG would have preferred 
data from the latest cut-off and centrally assessed PFS 
instead of locally assessed PFS.
The economic model described in the CS was considered 
by the ERG to meet the NICE reference case to a reason-
able extent and was mostly in line with the decision prob-
lem specified in the scope. After correcting the errors and 
implementing the changes described in the previous section, 
the ERG base-case analysis yielded an ICER that is above 
accepted NICE thresholds. In addition, owing to the high 
uncertainty surrounding the ICER because of several struc-
tural assumptions in the model (e.g. regarding PFS/OS sur-
rogacy, the choice of the parametric distribution to extrapo-
late first-line PFS/TTD and third-line treatment acquisition 
costs), the ERG deemed that the uncertainty around the cost-
effectiveness estimates of ribociclib was substantial.
3.7.1  Key Methodological Issues
The CS model type was different from most of the models 
submitted in previous related breast cancer appraisals, and a 
discrete-event simulation approach was followed. The ERG 
considered the modelling approach plausible; however, it 
found some of the assumptions (e.g. full PFS to OS surro-
gacy assumption, using unadjusted/unmatched data from the 
BOLERO-2 trial upon progression from the first-line treat-
ment and selection of exponential distribution for model-
ling first-line PFS and TTD) as debateable. Furthermore, the 
ERG was doubtful on the choice of some of the input param-
eters for the cost-effectiveness model, such as the treatment 
Table 1  List of corrections/adjustments to obtain the evidence review group preferred base case
CS company submission, OS overall survival, PFS progression-free survival
Change # Description
1 Fixing programming errors (mostly affected scenario analyses)
2 Updating the PFS-related clinical model inputs for the first line with the MONALEESA-2 data from the most recent data cut-off date 
(January 2017)
3 Incorporating the wastage costs (for the unused tablets in the last treatment cycle)
4 Using the inflation-adjusted post-progression treatment-related cost estimate from the fulvestrant appraisal (£1140) for monthly third-
line treatment costs [32]
5 Changing the modelling of the post-treatment discontinuation survival after second-line chemotherapy (so that the arbitrary Weibull 
scale parameter assumption in the CS is not used)
6 Implementing the partial PFS to OS surrogacy approach. This de novo approach decreases the time spent in states after first-line PFS 
in the ribociclib arm of the model in such a way that it would result in a “gain in median OS/gain in median PFS” ratio close to 
38.5% (4.2 months/10.9 months) from the PALOMA-1 trial, instead of the full PFS to OS surrogacy or threshold-based PFS to OS 
surrogacy approaches in the company CS
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costs in the progressed disease state (corresponding to third 
and further lines of therapy).
In the original CS, a detailed explanation of the underly-
ing Visual Basic codes and functions operationalising the 
discrete-event simulation in the cost-effectiveness analysis 
calculations was not provided. Understanding and verifica-
tion of the logic of the discrete-event simulation were pos-
sible only after the details and an explanation of the non-
transparent codes were provided, upon the request of the 
ERG, in the company’s response to the clarification letter. 
Because of this delay of provision of the coding details, the 
ERG could not conduct a full-scale technical verification, 
but rather some black-box testing to check the plausibility 
of the results.
The recent appraisal of palbociclib [17], another cyclin-
dependent kinase 4 and 6 inhibitor licenced for the same 
indication (first-line treatment of HR+/HER2− breast 
cancer), provided an opportunity to compare the evidence 
between two appraisals. In both of them, the comparator was 
the same, letrozole monotherapy; therefore, it was expected 
that the cost-effectiveness results, specifically pertaining to 
the control arm in both appraisals would be similar. How-
ever, the results differed substantially between TA495 (pal-
bociclib) and TA496 (ribociclib). The ERG noticed the dif-
ferences in modelling approaches (discrete-event simulation 
for TA496 vs. partitioned survival modelling for TA495) 
and some of the non-confidential input choices (e.g. PFS/
OS parametric modelling based on MONALEESA-2 and 
BOLERO-2 for TA496 [4] vs. PALOMA-2 and PALOMA-1 
for TA495 [17], and different utility inputs). However, the 
exact underlying reason of the gap between the results of 
these two appraisals could not be exactly pinpointed, as 
there was no access to the full details of the palbociclib 
submission.
4  National Institute for Health and Care 
Excellence Guidance
4.1  Company Changes to the Model and the First 
Appraisal Committee Meeting
The company, before the first ACM, updated its base case 
according to the ERG critique. In the new company base 
case, an enhanced PAS discount was proposed, and change 
#1, #2, #3 and #5 from Table 1 were implemented in the new 
company base case.
The company did not incorporate the fourth (considering 
the treatment costs in the progressed disease state) and the 
sixth (partial PFS to OS surrogacy reflecting OS/PFS gain 
of PALOMA-1 trial [31]) change of the ERG preferred base 
case in Table 1. Instead, the impact of these changes in the 
updated company base case was explored in the scenario 
analyses in the presence of the enhanced PAS discount. In 
the updated company base case and de-novo scenario analy-
ses, incremental QALYs gained for ribociclib were between 
0.53 and 0.89. The ICER values in the base-case and the sce-
nario analyses with the new enhanced PAS were around the 
acceptable thresholds. The probabilistic sensitivity analysis 
results were in line with the deterministic base-case results.
The committee considered the company’s decision prob-
lem and noted that it was in line with the NICE scope. Addi-
tionally, the committee concluded that the MONALEESA-2 
trial [16] formed suitable evidence on the clinical efficacy 
of ribociclib, in terms of PFS. However, the OS benefit of 
ribociclib was deemed uncertain, owing to the immaturity 
of the data. The increased incidence of AEs associated with 
ribociclib was acknowledged by the committee but it was 
deemed as acceptable.
The committee deferred the decision in this meeting 
because (1) the approach the company followed in the eco-
nomic model was different from most of the other models 
used in oncology technology appraisals; (2) the gap between 
the cost-effectiveness results from the model used in this 
submission and the model used in the palbociclib appraisal 
was substantial; and (3) some of the ribociclib model 
results were deemed to be counterintuitive (e.g. a decrease 
in survival gain resulted in ribociclib becoming more cost 
effective).
Therefore, the Decision Support Unit (DSU) was asked 
to support the committee to assess the validity of the model-
ling and the PFS to OS surrogacy approach, to compare the 
evidence between the ribociclib and palbociclib appraisals 
and pinpoint the main source of uncertainty, and to appraise 
the quality of the evidence to support these assumptions.
4.2  Decision Support Unit Analyses and the Second 
Appraisal Committee Meeting
In the second ACM, the main results of the DSU analysis 
were discussed [33]. The DSU conducted a literature review 
on the PFS to OS surrogacy approach and conducted some 
additional validation efforts on the CS model and provided 
a detailed comparison between the evidence from both ribo-
ciclib and palbociclib appraisals. It agreed that the model 
structure of the company was different from most of the 
other appraisals in oncology, but reasonably acceptable 
for decision making. Additionally, the DSU added that the 
BOLERO-2 trial [21] data, which were used in modelling 
of the patients receiving second-line treatment, seemed to 
be representative of patients progressing after the first-line 
treatment in MONALEESA-2.
It was unclear to the DSU if a full PFS to OS surrogacy 
is a valid approach. While the findings from the literature 
suggested that a PFS gain would likely result in an OS gain, 
there is no clear relationship. The DSU noted that the update 
 N. C. Büyükkaramikli et al.
of the PALOMA-1 study indicates a ratio smaller than 38%, 
but provided results for both full and partial PFS to OS sur-
rogacy approaches suggested by the ERG.
The DSU conducted several black-box tests and compared 
the CS ribociclib model with the CS palbociclib appraisal. It 
was suggested that the CS model had no additional program-
ming errors other than those the ERG had identified, and 
that the difference between the cost-effectiveness results of 
these two models was because of differences in modelling 
assumptions and input choices and not the result of program-
ming errors.
Further, the DSU scrutinised the impact of the third and 
later line treatment costs on the ICER under full and partial 
PFS to OS surrogacy assumptions. The DSU confirmed that 
the counterintuitive behaviour observed in some parameter 
realisations (e.g. ribociclib becomes more cost effective 
when there is less survival gain) is the result of the costs 
and effects assigned in the progressed state and how cost 
effective third and later line treatment is in comparison to 
first-line treatment.
Furthermore, the DSU noted the wide gap between mod-
elled PFS and TTD, and added that this wide gap was not in 
line with the reported treatment discontinuation proportions 
in the trial. According to the DSU, the Weibull distribution 
would provide a more plausible fit for PFS and TTD, as 
it would lead to a smaller difference between them. Using 
Weibull distribution for PFS and/or TTD would increase 
the ICER.
Additionally, the DSU added that the utility input used 
for the PFS1 state from the MONALEESA-2 trial, which 
was based on EQ-5D-5L, should be mapped into EQ-5D-3L 
values, based on the NICE position statement published a 
few weeks before the second ACM [34]. Additionally, an 
alternative utility input for the PFS2 state was suggested, 
which was derived from Mitra et al. [35]. This value was 
based on EQ-5D scores and was in line with the NICE refer-
ence case, unlike the original CS values that were based on 
a vignette valuation. Using these utilities (NICE reference 
case) would increase the ICER.
The DSU concluded that the treatment cost in third and 
later lines has a big impact on the ICER, especially in the 
partial PFS to OS surrogacy approach. It deemed that both 
estimates from the company (£2000) and the ERG (£1140) 
probably overestimated the actual treatment costs but con-
sidered the ERG’s estimate to be more plausible. In line with 
the ERG’s analyses, the ICER increased with lower third/
later line treatment costs in the partial PFS to OS surrogacy 
approach. Furthermore, the DSU emphasised that the com-
pany’s assumptions on dose reductions have a great impact 
on the ICER, and if all patients received a full licenced dose, 
the ICER would increase substantially.
The committee accepted that the model is appropriate for 
decision making and acknowledged the uncertainties and the 
differences in terms of ICERs between different scenarios 
presented by the ERG and by the DSU. However, it was 
decided that the majority of the plausible scenarios resulted 
in ICER figures that were higher than the range normally 
considered to be a cost-effective use of NHS resources.
4.3  Final Guidance
The company revised its base case (post first ACD) accord-
ing to the findings of the DSU analysis. The company’s revi-
sions in the new base case are summarised in Table 2.
The resulting ICER of the revised base case was below 
the threshold of £30,000/QALY. The company provided 
some exploratory scenario analyses to reflect the impact of 
some of the conflicting input choices (e.g. utility and third 
and later line treatment costs) and assumptions (e.g. PFS to 
OS surrogacy and PFS/TTD extrapolation) on the ICER. 
The ERG verified the results of the revised base case of the 
company.
The company considered some of the alternative inputs 
suggested by the DSU as implausible. First, the company 
suggested that a ribociclib dose reduction was based on the 
trial and would be observed in real clinical practice. Second, 
the use of the new utility inputs from Mitra et al. [35] was 
considered to be inconsistent with the previous breast cancer 
appraisals, where the utility values from Lloyd et al. [23] 
were used. In addition, the company maintained its position 
on the PFS/TTD extrapolation in the first line, and argued 
that the gap between the TTD and PFS was observed from 
the Kaplan–Meier curves from the MONALEESA-2 trial, as 
well. Finally the company disagreed with the third and later 
line treatment cost estimate of the ERG (£1140) and DSU 
(lower than £1140) because the source for the cost estimate 
(i.e. TA239, appraisal of fulvestrant in breast cancer) dated 
back to 2009 and the treatment costs would be higher owing 
to the newer treatments available in the market.
Table 2  List of revisions to the company base case after the second 
Appraisal Consultation Document
PAS patient access scheme, PFS progression-free survival, PFS1 
first-line progression-free survival, PFS2 second-line progression-
free survival, TTD time to treatment discontinuation
Change # Description
1 Second enhanced PAS discount
2 Updated utility inputs for PFS1 (3L mapped EQ-5D 
utilities from the MONALEESA-2) and PFS2 (from 
Mitra et al. [35])
3 PFS (local assessment) and TTD exponential extrapola-
tion for the first-line treatment, both based on a Janu-
ary 2017 data cut-off
4 £1500 as the treatment cost estimate for third and later 
lines
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The committee concluded that a degree of partial PFS 
to OS surrogacy is probably more likely than full surro-
gacy; however, the magnitude of the relationship was highly 
uncertain and both the full and partial PFS to OS surrogacy 
assumption results would be considered in its decision mak-
ing. The committee initially preferred the Weibull curve for 
PFS and TTD extrapolation because it reduced the differ-
ence between TTD and PFS in the first line to the expected 
levels. However, the Cancer Drug Fund clinical lead noted 
that extrapolation using the exponential curve appeared to 
provide clinically reasonable results for PFS, and that there 
was some justification in using the Weibull curve to model 
the TTD. The committee then agreed that there are a num-
ber of ways to extrapolate PFS and TTD in the model. It 
therefore concluded that there was uncertainty about which 
extrapolations are the most appropriate.
The committee deemed the utility values in the revised 
company base case as appropriate for decision making, but 
noted that the 3L mapped utilities from the MONALEESA-2 
trial in the first line may undervalue the quality of life of 
patients in the progression-free health state. The commit-
tee also found the company’s approach of using trial-based 
ribociclib dose reduction data appropriate.
Finally, the committee noted different treatment cost esti-
mates for the third and later line treatment costs from the 
company, the ERG, the DSU and the Cancer Drug Fund 
lead. It also noted that in the ongoing appraisal of palboci-
clib, an average cost of subsequent therapies was calculated 
as £1200 per month. Therefore, the committee concluded 
that it would consider costs in the region of £1140–£1200 
in its decision making.
Overall, the committee agreed that the cost-effectiveness 
estimates are subject to high uncertainty given the assump-
tions about PFS to OS surrogacy, PFS and TTD extrapola-
tions, and the cost of subsequent (i.e. third and later line) 
treatments. Taking into account the uncertainties in the cal-
culation of the cost-effectiveness estimates, it was persuaded 
that there were plausible cost-effectiveness estimates broadly 
in the range that could be considered a cost-effective use 
of NHS resources. Therefore, ribociclib was recommended 
as a first-line treatment option for patients with HR+/
HER2− breast cancer.
5  Conclusions
This STA illustrated that using data from different data cut-
offs and using locally assessed or centrally assessed PFS 
data can have a substantial impact on both clinical and cost-
effectiveness results. The ERG preferred all clinical inputs 
(i.e. PFS, TTD, death probabilities and AEs) to be based on 
the latest (the most informative) data cut-off and PFS based 
on a central assessment, as locally assessed PFS could be 
biased because the blinding might have been flawed as a 
result of different incidences of AEs.
The modelling approach followed in this appraisal, 
discrete-event simulation, was different from most of the 
other modelling approaches in oncology. This modelling 
approach, as in all other approaches, has its own advan-
tages and disadvantages. New modelling approaches can be 
acceptable; however, it is essential that the underlying cod-
ing is transparent and the explanation of the programming 
is provided in the initial submission so that the critique can 
be completed in a timely manner.
Another interesting aspect of this STA was how the 
uncertainty surrounding the OS was tackled when the rel-
evant data were lacking. As the OS data from the trial 
were immature, different (e.g. partial or full) PFS to OS 
surrogacy approaches were followed in different scenario 
analyses, which were all taken into account in the deci-
sion-making process. It was also observed that under some 
parameter realisations, the third-line treatment cost esti-
mate became the most impactful parameter, hence char-
acterisation of the uncertainty surrounding that parameter 
was essential.
This STA further uncovered the complexity of deci-
sion making if two simultaneous appraisals provide some 
conflicting results, which might lead to additional doubts. 
However, these differences do not mean that the modelling 
approach/input choices from one of the appraisals are auto-
matically wrong. In the presence of such conflicting cases, 
it might be important to have a full understanding of the 
underlying causes of the differences. In these situations, an 
external member who can access data from both appraisals 
can prove useful. The committee may therefore (but also for 
other reasons), on occasion benefit from external points of 
view and external support (e.g. DSU) in addition to those 
of the ERG.
Last, this STA showed that the iterative nature of 
appraisal meetings may provide an opportunity to find a 
middle ground between the company assumptions and the 
ERG point of view. The company may provide enhanced 
PAS discounts to reduce the uncertainty surrounding the 
cost effectiveness of a drug in this process.
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